Skip to content

Study on the Spatial Distribution of Perivascular Adipose Tissue around the Carotid Artery as a Predictor of Plaque Vulnerability

Study on the Spatial Distribution of Perivascular Adipose Tissue around the Carotid Artery as a Predictor of Plaque Vulnerability

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111991
Enrollment
Unknown
Registered
2025-11-09
Start date
2025-09-02
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Stenosis

Interventions

Gold Standard:Based on non-contrast high-resolution magnetic resonance imaging (HR-MRI) of the carotid artery, plaque vulnerability assessed using the MRI-PlaqueView™ software [PlaqueView (Beijing) Di
Index test:Based on carotid artery CTA, the spatial distribution characteristics of perivascular adipose tissue at the carotid bifurcation analyzed using Slicer software (v 5.8.1) served as the diagno

Sponsors

The First Medical Center of the PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 40 years; 2. Presence of atherosclerotic plaque at the carotid bifurcation or the origin of the internal carotid artery on either side, as detected by ultrasound or carotid artery CTA; 3. Luminal stenosis >= 50% in asymptomatic patients, or >= 30% in symptomatic patients with carotid stenosis (e.g., transient ischemic attack or ischemic stroke); 4. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of previous carotid artery surgery, radiotherapy, or stent implantation; 2. Poor image quality of carotid artery CTA or HR-MRI that is inadequate for post-processing analysis (e.g., severe motion artifacts, insufficient contrast filling, etc.); 3. Coexistence of other non-atherosclerotic vascular diseases (e.g., Takayasu arteritis, arterial dissection, fibromuscular dysplasia, etc.); 4. Severe renal insufficiency (eGFR < 30 ml/min/1.73m^2) precluding contrast-enhanced CTA; 5. Presence of any contraindication to MRI examination (e.g., non-compatible metallic implants, claustrophobia, etc.); 6. Presence of systemic diseases affecting lipid metabolism (e.g., Cushing's syndrome, systemic lupus erythematosus, etc.).

Design outcomes

Primary

MeasureTime frame
The area under the working characteristic curve;

Countries

China

Contacts

Public ContactWang Jun

The First Medical Center of the PLA General Hospital

wangjun301@126.com+86 139 1075 6623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026